Report Library
All Reports
Triple Negative Breast Cancer KOL Interview
February 09, 2016
If you are a KOL Insight Subscriber, please access this report here, in our KOL
Insight portal (Subscribers only).
Highlights
For our disclosures, please read the BioMedTracker Research Standards.
Highlights
- Abraxane is this oncologist’s first choice for treating metastatic triple negative breast cancer because it is so well tolerated (CELG).
- Halaven is the next go-to drug for metastatic triple negative breast cancer. Its main disadvantage is that it causes neutropenia (Eisai).
- KOL avoids using Ixempra because it has so many side effects (R-Pharm Group).
- There is a strong need for new drugs for metastatic triple negative breast cancer. With the currently available drugs, oncologists are not seeing much of a response in patients who had two or more lines of therapy.
- There is also a need for drugs that can cross the blood-brain barrier. The KOL uses Abraxane and Xeloda for brain mets (CELG, Roche) .
- PARP inhibitors are going to be a welcome addition to the arsenal but they will only be used in a small subpopulation that carries a BRCA mutant.
- PD1/PD1L inhibitors will represent a new target and so will see a quick uptake into clinical care because it looks like they are well tolerated (MRK, Roche).
- Patients with metastatic triple negative breast cancer are sent out for next-gen sequencing but often the results are not actionable as drugs that target the mutated gene are not yet approved for breast cancer.
For our disclosures, please read the BioMedTracker Research Standards.
| Indications Covered: | Breast Cancer |
Additional Resources: